ClariVest Asset Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

ClariVest Asset Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-8,244	Closed	-$538K	–	791
2018 Q1	$538K	Sell	8,244 -23	-0.3%	-$1.63K	0.01%	497
2017 Q4	$604K	Buy	+8,267	New	+$684K	0.01%	471

Other funds holding LUMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClariVest Asset Management's LUMO Position: Q2 2018 in Review

ClariVest Asset Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2018, closing a stake of 8,244 shares — an estimated $538K sold.

ClariVest Asset Management first reported a position in LUMO in Q4 2017 and held it in 2 quarters. The position peaked at $604K in Q4 2017. 106 funds tracked by Wall St. Rank hold LUMO as of Q2 2018.

ClariVest Asset Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
ClariVest Asset Management sold 8,244 Lumos Pharma, Inc. Common Stock shares in Q2 2018, an estimated $538K.
ClariVest Asset Management first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
ClariVest Asset Management's Lumos Pharma, Inc. Common Stock position peaked at $604K in Q4 2017.
106 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2018.

Based on ClariVest Asset Management's 13F filing for Q2 2018, filed 10 Aug 2018.